Difference between revisions of "Lestaurtinib (CEP-701)"
Jump to navigation
Jump to search
m |
m |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | + | ==Mechanism of action== | |
| + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lestaurtinib NCI Drug Dictionary]: An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. | ||
==Also known as== | ==Also known as== | ||
| Line 8: | Line 9: | ||
[[Category:FLT3 inhibitors]] | [[Category:FLT3 inhibitors]] | ||
| − | [[Category: | + | [[Category:JAK2 inhibitors]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Latest revision as of 11:24, 23 September 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3.
Also known as
- Code name: CEP-701